• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsPress ReleasesPressreleases 2013

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Press releases 2013

  • All
  • Regulatory release

Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer

5 December 2013 Read more

Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer

5 December 2013 Read more

Immunicum : Sven Andréasson new Board member

3 December 2013 Read more

Immunicum : Sven Andréasson new Board member

3 December 2013 Read more

Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.

25 October 2013 Read more

Immunicum's patent application regarding the Company's core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.

25 October 2013 Read more

Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer

23 October 2013 Read more

Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer

23 October 2013 Read more

The Regional Ethical Review Board approves start of Immunicum’s planned liver cancer vaccine study

21 August 2013 Read more

The Regional Ethical Review Board approves start of Immunicum's planned liver cancer vaccine study

21 August 2013 Read more

Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August

19 August 2013 Read more

Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August

19 August 2013 Read more

Company name trade mark registered in the EU

12 August 2013 Read more

Company name trade mark registered in the EU

12 August 2013 Read more

The Medical Products Agency clears unique Swedish cancer vaccine for clinical tests in liver cancer patients

22 July 2013 Read more

The Medical Products Agency clears unique Swedish cancer vaccine for clinical tests in liver cancer patients

22 July 2013 Read more

Immunicum recruits a new Chief Operating Officer

1 July 2013 Read more

Immunicum recruits a new Chief Operating Officer

1 July 2013 Read more

Another trademark registered in the EU

25 June 2013 Read more

Another trademark registered in the EU

25 June 2013 Read more

Trade mark registered in the EU

20 June 2013 Read more

Trade mark registered in the EU

20 June 2013 Read more

Immunicum receive extended SME-status from the European Medicines Agency

18 June 2013 Read more

Immunicum receive extended SME-status from the European Medicines Agency

18 June 2013 Read more

Promising data for cancer vaccine INTUVAX™ in the treatment of kidney cancer

20 May 2013 Read more

Promising data for cancer vaccine INTUVAX(TM) in the treatment of kidney cancer

20 May 2013 Read more

Immunicum seeks approval for a clinical phase I/II-trial in liver cancer

30 April 2013 Read more

Immunicum seeks approval for a clinical phase I/II-trial in liver cancer

30 April 2013 Read more

Immunicum conducts a private placement of 8,8 million SEK

28 March 2013 Read more

Immunicum conducts a private placement of 8,8 million SEK

28 March 2013 Read more

Immunicum AB (publ) issues new shares before listing on NASDAQ OMX First North

4 March 2013 Read more

Immunicum AB (publ) issues new shares before listing on NASDAQ OMX First North

4 March 2013 Read more
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve